I for one hope that they have reconsidered taking
Post# of 148171
If the results are good, but not quite good enough to get a halt, we could benefit from having the data with respect to accelerating enrollment.
We have an adaptive trial, so I believe we can increase the size of it if needed.
If our data shows a pvalue of say .06, but a 50% reduction in mortality, I would think that data would serve to substantially increase enrollment.